About

Primary biliary cholangitis is an autoimmune liver disease where the immune system slowly destroys the organ's small bile ducts, leading to a toxic buildup of bile. Saroglitazar is an oral drug that activates two key receptors (PPAR α/γ) to regulate how the liver handles fats and inflammation. This dual action may help reduce the bile buildup and liver damage that drives the disease's progression.